December 22, 2020

GI Oncology Conference

GI Oncology Conference

——————————————————————————————————–

March 28th, 2021

7:15 am PST – 1:10 pm PST

Held Virtually on Zoom

OVERVIEW

The care of GI cancers is advancing at a rapid pace. ‘Advances in Gastrointestinal (GI) Cancers: A Virtual International Conference’ is a CME-accredited virtual conference that brings together the leading experts from around the world to discuss recent advances in the field of GI oncology with a focus on biomarker-driven therapies, immuno-oncology, and clinical applications of the recent advances across various GI tumor types. This meeting will provide an opportunity to hear from the leading national and international experts on how recently published data would change practice, some of which will have immediate clinical applications. Furthermore, each session will have multiple segments on novel emerging treatment paradigms likely to transform the care of GI cancers in the near future.

This virtual conference is intended to propagate new information to augment the knowledge and clinical competence of the cancer care providers in the following areas:

  • Emerging role of immunotherapy in the field of GI cancers
  • Evolving role of circulating tumor DNA (ctDNA) in the management of colorectal cancer
  • Novel emerging therapies for pancreatic cancer
  • Novel treatment options for rectal cancer, including non-operative protocol 
  • Trends, challenges, and controversies in the management of GI cancers

TARGET AUDIENCE

  • Oncologists
  • Residents/Fellows
  • NPs/PAs
  • Pharmacists
  • Nurses

EDUCATIONAL OBJECTIVES

Upon successful completion of this educational activity, participants will be able to:

  • Discuss the role of immunotherapy in various GI cancers
  • Understand the role of novel biomarkers directing the therapy of GI cancers.
  • Compare and contrast the safety and efficacy of competing therapeutic strategies  influencing the management of GI cancers
  • Integrate emerging data into the treatment strategies of GI cancers
  • Identify the areas where precision medicine driven therapy personalizations play an essential role.


CREDIT STATEMENT

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 4.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 4.25 Contact Hours.

ABSM Maintenance of Certificate Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

FACULTY

Dr. Siddhartha Yadav

Mayo Clinic

Dr. Bhawna Sirohi

Max Healthcare

Dr. Sakti Chakrabarti

Medical College of Wisconsin

Dr. Axel Grothey

West Cancer Center

Dr. Andrew Coveler

University of Washington

Dr. Ghassan Abou-Alfa

Memorial Sloan Kettering

Dr. Joseph Chao

City of Hope

Dr. Eileen M. O’Reilly

Memorial Sloan Kettering

Dr. Rachna T. Shroff

University of Arizona

Dr. Aparna R. Parikh

Harvard Medical School

Dr. Daniel Catenacci

The University of Chicago